{"nctId":"NCT00533273","briefTitle":"Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease","startDateStruct":{"date":"2007-08","type":"ACTUAL"},"conditions":["Advanced Dupuytren's Disease"],"count":66,"armGroups":[{"label":"AA4500 0.58 mg","type":"EXPERIMENTAL","interventionNames":["Biological: collagenase clostridium histolyticum"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: collagenase clostridium histolyticum"]}],"interventions":[{"name":"collagenase clostridium histolyticum","otherNames":["XIAFLEX®","AA4500"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with a diagnosis of advanced Dupuytren's disease, with a fixed flexion deformity of at least one finger, other than the thumb, that had a contracture at least 20°, but not greater than 100°, for MP (80° for PIP) joints, caused by a palpable cord.\n* Had a positive \"table top test,\" defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.\n* Were naive to AA4500 treatment\n* Were judged to be in good health, based upon the results of a medical history, physical examination, and safety laboratory profile.\n\nExclusion Criteria:\n\n* Had a chronic muscular, neurological, or neuromuscular disorder that affected the hands.\n* Had received a treatment for advanced Dupuytren's disease, including surgery (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon on the selected primary joint within 90 days before the first dose of study drug.\n* Had a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition, which in the investigator's opinion, would make the subject unsuitable for enrollment in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Reduction in Primary Joint Contracture to 5° or Less","description":"Successfully treated or clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Improvement in Primary Joint After the Last Injection","description":"Clinical improvement in primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"14.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Reduction From Baseline Contracture of Primary Joint After the Last Injection","description":"Percent change in degree of contracture of primary joint measured as 100 \\* (baseline contracture - last available post-injection contracture)/baseline contracture","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.5","spread":"29.21"},{"groupId":"OG001","value":"13.6","spread":"26.10"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Range of Motion in Primary Joint After the Last Injection","description":"Change in degree of range of motion in primary joint measured as last available post-injection range of motion - baseline range of motion","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.4","spread":"17.77"},{"groupId":"OG001","value":"7.6","spread":"14.88"}]}]}]},{"type":"SECONDARY","title":"Time to Reach Clinical Success in Primary Joint","description":"Clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null},{"groupId":"OG001","value":"95.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Success in Primary Joint After the First Injection","description":"Clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.7","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Improvement in Primary Joint After the First Injection","description":"Clinical improvement in primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Reduction From Baseline Contracture of Primary Joint After the First Injection","description":"Percent change in degree of contracture of primary joint measured as 100 \\* (baseline contracture - last available post-injection contracture prior to next injection)/baseline contracture","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.5","spread":"31.74"},{"groupId":"OG001","value":"6.0","spread":"20.79"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Range of Motion in Primary Joint After the First Injection","description":"Change in degree of range of motion in primary joint measured as last available post-injection range of motion prior to the next injection - baseline range of motion","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":"17.41"},{"groupId":"OG001","value":"3.6","spread":"9.51"}]}]}]},{"type":"SECONDARY","title":"Reduction in Non-primary Joint Contracture to 5° or Less After the Last Injection","description":"Successfully treated or clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Improvement in Non-Primary Joint After the Last Injection","description":"Clinical improvement in non-primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Reduction From Baseline Contracture of Non-Primary Joint After the Last Injection","description":"Percent change in degree of contracture of non-primary joint measured as 100 \\* (baseline contracture - last available post-injection contracture)/baseline contracture","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.4","spread":"34.63"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Range of Motion in Non-Primary Joint After the Last Injection","description":"Change in degree of range of motion in non-primary joint measured as last available post-injection range of motion - baseline range of motion","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.2","spread":"16.80"}]}]}]},{"type":"SECONDARY","title":"Time to Reach Clinical Success in Non-Primary Joint","description":"Clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Success in Non-Primary Joint After the First Injection","description":"Clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Improvement in Non-Primary Joint After the First Injection","description":"Clinical improvement in non-primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Reduction From Baseline Contracture of Non-Primary Joint After the First Injection","description":"Percent change in degree of contracture of non-primary joint measured as 100 \\* (baseline contracture - last available post-injection contracture prior to next injection)/baseline contracture","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.7","spread":"38.37"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Range of Motion in Non-Primary Joint After the First Injection","description":"Change in degree of range of motion in non-primary joint measured as last available post-injection range of motion prior to the next injection - baseline range of motion","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5","spread":"17.52"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":63},"commonTop":["Oedema peripheral","Contusion","Pain in extremity","Injection site pain","Injection site haemorrhage"]}}}